down arrow

Sarda Proteins

  • Market Cap: Micro Cap
  • Industry: Edible Oil
  • ISIN: INE995U01011
  • NSEID:
  • BSEID: 519242
  • View on BSE
INR
68.82
3.27 (4.99%)
BSENSE

Mar 05

BSE+NSE Vol: 1.19 k

Access older stock analysis version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationTechnical Trend Update: Sarda Proteins witnessed a change in Technical Grade on 02 Mar 2026. Click here to discover latest technical change!
stock-summaryPrice Point
High/Low

1Day

62.2868.82

52 Week

59.95137.45
Valuation
Technical
Day's Volume

CASH

1.19 k (51.88%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

Is Sarda Proteins overvalued or undervalued?

09-Jun-2025

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

View full answer

What is the technical trend for Sarda Proteins?

09-Jun-2025

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

View full answer

How has been the historical performance of Sarda Proteins?

01-Dec-2025

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

View full answer

When is the next results date for Sarda Proteins Ltd?

11-Feb-2026

The next results date for Sarda Proteins Ltd is 14 February 2026.

The next results date for Sarda Proteins Ltd is scheduled for 14 February 2026.

View full answer

Should I buy, sell or hold Sarda Proteins Ltd?

15-Feb-2026

Why is Sarda Proteins Ltd falling/rising?

05-Mar-2026

As of 04-Mar, Sarda Proteins Ltd's stock price has declined to 65.55, down 5.0%, due to underperformance relative to its sector and negative market sentiment. The stock has shown erratic trading patterns and decreased investor participation, leading to a significant drop in confidence.

As of 04-Mar, Sarda Proteins Ltd is experiencing a decline in its stock price, currently at 65.55, which reflects a change of -3.45 or -5.0%. This drop can be attributed to several factors. Firstly, the stock has underperformed its sector by -2.39% today, indicating weaker performance relative to its peers. Additionally, the stock opened with a loss of -5% and reached an intraday low of Rs 65.55, suggesting a negative market sentiment.<BR><BR>Moreover, the stock has shown erratic trading patterns, not trading on 2 out of the last 20 days, which may contribute to investor uncertainty. The delivery volume has also significantly decreased, with a drop of -49.68% against the 5-day average, indicating falling investor participation. <BR><BR>In terms of performance over various periods, the stock has declined by -11.34% over the past month and -44.85% over the past year, contrasting sharply with the Sensex, which has gained +8.39% over the same year. Although the stock has performed well over a 5-year period with a +590.00% increase, the recent trends suggest a troubling decline that is affecting investor confidence and contributing to the current price drop.

View full answer

Which are the latest news on Sarda Proteins?

05-Mar-2026
When is the next results date for Sarda Proteins Ltd?
Sarda Proteins Falls 9.74%: Sharp Gap Down and Persistent Selling Pressure

Compare Sarda Proteins with Similar Stocks

Madhusudan Inds.Natraj ProteinsPrima Industries
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.02
  • The company has been able to generate a Return on Equity (avg) of 3.91% signifying low profitability per unit of shareholders funds
2

Flat results in Dec 25

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Edible Oil

stock-summary
Market cap

INR 11 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

22

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

-4.82%

stock-summary
Price to Book

4.96

Revenue and Profits:
Net Sales:
0 Cr
(Quarterly Results - Dec 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.24%
0%
-8.24%
6 Months
0%
0%
0.0%
1 Year
-42.1%
0%
-42.1%
2 Years
0%
0%
0.0%
3 Years
19.27%
0%
19.27%
4 Years
86.0%
0%
86.0%
5 Years
624.42%
0%
624.42%

Sarda Proteins for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is scheduled for 14 February 2026....

Read full news article

Sarda Proteins Falls 9.74%: Sharp Gap Down and Persistent Selling Pressure

Key Events This Week

29 Dec: Sharp gap down and intraday low at Rs.74.11 (-9.74%)

30 Dec - 2 Jan: Stock price remained static at Rs.74.11 despite Sensex gains

2 Jan: Week closes at Rs.74.11, down 9.74% for the week

Week Open
Rs.82.11
Week Close
Rs.74.11
-9.74%
Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Announcements stock-summary

Board Meeting Outcome for Results - Dec 2025

14-Feb-2026 | Source : BSE

Results for the quarter and nine months ended on 31st Dec 2025

Board Meeting Intimation for Results For The Quarter Ended On Dec 2025

10-Feb-2026 | Source : BSE

Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended on 31st December 2025

Closure of Trading Window

27-Dec-2025 | Source : BSE

Intimation of Trading Window Closure

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
2.51%
EBIT Growth (5y)
-21.93%
EBIT to Interest (avg)
-0.02
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
5.28
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-0.03%
ROE (avg)
3.91%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
22
Price to Book Value
4.96
EV to EBIT
-11.34
EV to EBITDA
-11.34
EV to Capital Employed
4.91
EV to Sales
0.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.66%
ROE (Latest)
-4.82%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ritika Vegetable Oil Private Limited (0.0%)

Highest Public shareholder

Guttikonda Vara Lakshmi (3.57%)

Individual Investors Holdings

90.94%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -94.19% vs -60.73% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -130.00% vs 181.63% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.25",
          "val2": "4.30",
          "chgp": "-94.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.12",
          "val2": "0.30",
          "chgp": "-140.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.12",
          "val2": "0.40",
          "chgp": "-130.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-48.00%",
          "val2": "6.98%",
          "chgp": "-54.98%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.26",
          "val2": "0.14",
          "chgp": "10,800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.19",
          "val2": "0.02",
          "chgp": "-1,050.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.09",
          "val2": "0.03",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.25%",
          "val2": "14.29%",
          "chgp": "-15.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.51",
          "val2": "24.19",
          "chgp": "-35.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.31",
          "val2": "0.12",
          "chgp": "-358.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.21",
          "val2": "0.13",
          "chgp": "-261.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.00%",
          "val2": "0.50%",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1,760.77% vs -77.59% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -50.00% vs 166.67% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.19",
          "val2": "1.30",
          "chgp": "1,760.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.02",
          "val2": "-0.14",
          "chgp": "114.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.01",
          "val2": "0.02",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.08%",
          "val2": "-10.77%",
          "chgp": "10.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
0.25
4.30
-94.19%
Operating Profit (PBDIT) excl Other Income
-0.12
0.30
-140.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.12
0.40
-130.00%
Operating Profit Margin (Excl OI)
-48.00%
6.98%
-54.98%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -94.19% vs -60.73% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -130.00% vs 181.63% in Sep 2025

All Quarterly Resultsstock-summary

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
15.26
0.14
10,800.00%
Operating Profit (PBDIT) excl Other Income
-0.19
0.02
-1,050.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.09
0.03
-400.00%
Operating Profit Margin (Excl OI)
-1.25%
14.29%
-15.54%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024

All Half Yearly Resultsstock-summary

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
15.51
24.19
-35.88%
Operating Profit (PBDIT) excl Other Income
-0.31
0.12
-358.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.21
0.13
-261.54%
Operating Profit Margin (Excl OI)
-2.00%
0.50%
-2.50%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024

All Nine Monthly Resultsstock-summary

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
24.19
1.30
1,760.77%
Operating Profit (PBDIT) excl Other Income
0.02
-0.14
114.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.01
0.02
-50.00%
Operating Profit Margin (Excl OI)
0.08%
-10.77%
10.85%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 1,760.77% vs -77.59% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -50.00% vs 166.67% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Sarda Proteins Ltd stock-summary
stock-summary
Sarda Proteins Ltd
Micro Cap
Edible Oil
Sarda Proteins Limited was incorporated on December 03, 1991. The Company is mainly engaged in trading of Edible Oils and Agri Commodities, which includes wheat, Oil Seeds, Grains, Edible Oil, etc. The management of the Company was duly changed in FY 2018-19, pursuant to completion of acquisition process by Ritika Vegetable Oil Private Limited as per Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Company Coordinates stock-summary
Company Details
B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030
stock-summary
Tel: 91-144-2881392
stock-summary
http://www.sardaproteins.com
stock-summary
sardaproteins@yahoo.com
Registrar Details
Link Intime India Pvt Ltd., Narang Tower 44, Community Centre, Naraina Industrial Area , Phase - 1, New Delhi
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."